nach oben

Erschienen in:

2017 | OriginalPaper | Buchkapitel

11. Value Chain and CSR of Global Pharmaceutical Companies: A Framework to Define Practices

verfasst von : Nathalie Gimenes, Marielle A. Payaud

Erschienen in: Corporate Social Responsibility in the Post-Financial Crisis Era

Verlag: Springer International Publishing

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config

KI-gestützte Suche

Aus

Abstract

This chapter looks at the manner in which global pharmaceutical companies contribute to a better society. To answer this, the authors constructed a framework that allows the responsible practices deployed by the global pharmaceutical companies to be identified along the value chain. This framework offers a heuristic reasoning to facilitate the understanding of the cooperative strategies used by firms and describes the social obligations which companies think they must assume toward society. It is applied through an exploratory study filled with qualitative data obtained through corporate social responsibility (CSR) reports from 2013 of global pharmaceutical companies. At the end, the chapter offers examples from these companies to describe their CSR projects and derives an overall picture of pharmaceutical companies’ contribution toward society in the post-financial crisis.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

über 102.000 Bücher
über 537 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Finance + Banking
Management + Führung
Marketing + Vertrieb
Maschinenbau + Werkstoffe
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 340 Zeitschriften

aus folgenden Fachgebieten:

Bauwesen + Immobilien
Business IT + Informatik
Finance + Banking
Management + Führung
Marketing + Vertrieb
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Vorheriges Kapitel Exploring Post-Financial Crisis CSR Digital Communications by MNEs in Mexico

Nächstes Kapitel Fear, Loathing and Shale Gas. The Introduction of Fracking to the UK: A Case Study

Acquier, A., Daudigeos, T., & Valiorgue, B. (2011). Corporate social responsibility as an organizational and managerial challenge: The forgotten legacy of the corporate social responsiveness movement. M@ N@ Gement, 14(4), 222–250.AstraZeneca. (2013). AstraZeneca CSR Report. Retrieved September 15, 2014, from http://astrazeneca-annualsreport.com/2013/

Bergouignan, B., Claude, M., Montalban, M., Sakinç, M. E., & Smith, A. (2014). L’industrie pharmaceutique Régles, acteurs et pouvoir. Paris: La ducumentation Française.

Boidin, B., & Lesaffre, L. (2011). L’accès Des Pays Pauvres Aux Médicaments et La Propriété Intellectuelle: Quel Apport Des Partenariats Multiacteurs? Revue Internationale de Droit économique, 24(3), 325–350.Burell, G., & Morgan, G. (1979). Sociological Paradigms and Organization Analysis. Elements of Sociology of Corporate Life. Newcastle: Athenaeum Press.

Capron, M., & Quairel-Lanoizelée, F. (2004). Mythes et réalités de L’entreprise responsable. Paris: La Découverte.

Cavazzana-Calvo, M., & Debiais, D. (2011). Biomédicament, économie et innovation. Paris: Presses universitaires de France.

Donation Mectizan^® Program. (2013). Donation Mectizan ^® Program 2013. Retrieved July 14, 2015, from http://www.mectizan.org/

Gateaux, V., & Heitz, J.-M. (2008). L’accès Aux Médicaments: Un Défi Pour L’industrie Pharmaceutique. Humanisme et Entreprise, 286(1), 13–28.CrossRef

Gond, J.-P. (2011). La Responsabilité Sociale de L’entreprise Au-Delà Du Fonctionnalisme: Un Cadre D’analyse Pluraliste de L’interface Entreprise-Société. Revue Finance Contrôle Stratégie, 14(2), 37–66.

Gond, J.-P., & Igalens, J. (2014). La Responsabilité Sociale de L’entreprise. Paris: Presses universitaires de France.CrossRef

GSK. (2013a). New partnership between GSK and the Bill & Melinda Gates Foundation. Retrieved July 28, 2015, from http://us.gsk.com/en-us/media/press-releases/2013/new-partnership-between-gsk-and-the-bill-andamp-melinda-gates-foundation-to-accelerate-research-into-vaccines-for-global-health-needs/

GSK. (2013b). GSK CSR report. Retrieved September 15, 2014, from http://www.gsk.com/media/325156/annual-report-2013.pdf

Hoffmann, G., & Saulquin, J.-Y. (2009). Quand La RSE Revisite La Chaîne de Valeur. Management & Avenir, 28, 37–55.CrossRef

Jenkins, H. (2009). A “business opportunity” model of corporate social responsibility for small-and medium-sized enterprises. Business Ethics: A European Review, 18(1), 21–36.CrossRef

Johnson and Johnson. (2013a). Johnson and Johnson CSR report. Retrieved July 13, 2014, from http://www.jnj.com/sites/default/files/pdf/cs/2013-JNJ-Citizenship-Sustainability-Report-FINAL061914.pdf

Johnson and Johnson. (2013b). The patient assistance program JNJ. Retrieved July 13, 2014, from http://www.jjpaf.org/

Lewis, M. W., & Grimes, A. I. (1999). Metatriangulation: Building theory from multiple paradigms. Academy of Management Review, 24(4), 672–690.CrossRef

Lilly. (2013). Lilly CSR report. Retrieved October 13, 2014, from http://www.lilly.com/Documents/Lilly_2012_2013_CRreport.pdf

Martinet, A. C. (1984). Management Stratégique: Organisation et Politique. Paris: McGraw-Hill.

Martinet, A. C. (2006). Parties Prenantes, Management Stratégique et Politique. In M. Bonnafous-Boucher & Y. Pesqueux (Eds.), Décider Avec Les Parties Prenantes (pp. 9–18). Paris: La Découverte.CrossRef

Martinet, A. C., & Payaud, M. A. (2008). Formes de RSE et Entreprises Sociales. Une Hybridation Des Stratégies. Revue Française de Gestion, 180, 199–214.CrossRef

Martinet, A. C., & Payaud, M. A. (2009). Un Cadre Théorique Intégrateur Pour Le Management Stratégique «BOP». Revue de l’Organisation Responsable, 4, 19–30.CrossRef

Martinet, A. C., & Payaud, M. A. (2010). La Stratégie BOP à L’épreuve Des Pauvretés. Une Modélisation Dialogique. Revue Française de Gestion, 36(208–209), 63–81.CrossRef

Merck & Co. 2014. Merck & Co website. Retrieved September 15, from http://www.merck.com

Mills, A. (2002). La Science et La Technologie En Tant Que Biens Publics Mondiaux: S’attaquer Aux Maladies Prioritaires Des Pays Pauvres. Revue D’économie Du Développement, 16(1), 117–139.CrossRef

Novartis. (2013). Novartis CSR report. Retrieved January 28, 2014, from https://www.novartis.com/corporate-responsibility/metrics-and-reporting/cr-performance-report.shtml

Novartis. (2015). Novartis website. Retrieved July 15, from https://www.novartis.com/about-us/corporate-responsibility

Palazzo, G., & Wentland, M. (2011). Evaluation de la performance sociale et environnementale des entreprises. Retrieved July 15, 2015, from http://www.unil.ch/files/live//sites/unicom/files/shared/pdfs/etude.pdf

Pfizer. (2013). ProgramRxPathways ^TM. Retrieved September 20, 2014, from http://www.pfizerrxpathways.com

PWC. (2013). Rapport 686. Développement Durable Pharmaceutique. Retrieved July 15, 2015, from http://developpement-durable.pwc.fr/fr/approche-par-secteur-d-activite/secteur-pharmaceutique/

Roche. (2013a). Roche CSR report. Retrieved July 30, 2014, from http://www.roche.com/gb13e.pdf

Roche. (2013b). Roche website. Retrieved December 22, from http://www.roche.com/sustainability.htm

Sanofi. (2013). Sanofi CSR report. Retrieved May 6, 2014, from http://www.sanofi.com/Images/36400_Rapport_RSE_2013.pdf

Schneider, J. L., Wilson, A., & Rosenbeck, J. M. (2010). Pharmaceutical companies and sustainability: An analysis of corporate reporting. Benchmarking: An International Journal, 17(3), 421–434.CrossRef

Teva. (2013). Teva CSR report. Retrieved April 14, 2014, from http://www.teva-csr-report-2013.com/

Turcotte, M.-F. B., & Pasquero, J. (2007). L’industrie Pharmaceutique et Ses Responsabilités Sociales. In J. J. Levy & C. Garnier (Eds.), La Chaine Des Medicaments: Perspectives Pluridisciplinaires (pp. 200–257). Quebec: Presses de l’Université du Quebec.

Vogel, D. (2006). The market for virtue: The potential and limits of corporate social responsibility. Virginia: Brookings Institution Press.

WHO. (2013). Global programme to eliminate lymphatic filariasis. Retrieved July 15, 2015, from http://www.who.int/lymphatic_filariasis/en/

Titel: Value Chain and CSR of Global Pharmaceutical Companies: A Framework to Define Practices
verfasst von: Nathalie Gimenes
Marielle A. Payaud
Verlag: Springer International Publishing
Buch: Corporate Social Responsibility in the Post-Financial Crisis Era
Print ISBN: 978-3-319-40095-2

Electronic ISBN: 978-3-319-40096-9

Copyright-Jahr: 2017
DOI: https://doi.org/10.1007/978-3-319-40096-9_11